A case study of foliglurax, the first clinical mGluR4 PAM for symptomatic treatment of Parkinson’s disease: translational gaps or a failing industry innovation model?-Reference-Cited by-同舟云学术

A case study of foliglurax, the first clinical mGluR4 PAM for symptomatic treatment of Parkinson’s disease: translational gaps or a failing industry innovation model?

Published:2020-11-11 Issue:12 Volume:29 Page:1323-1338
ISSN:1354-3784
Container-title:Expert Opinion on Investigational Drugs
language:en
Short-container-title:Expert Opinion on Investigational Drugs

Author:

Doller Dario¹^ORCID,Bespalov Anton²³^ORCID,Miller Rob⁴,Pietraszek Malgorzata²,Kalinichev Mikhail⁵

Affiliation:

1. Alcyoneus ScienceWorks, LLC., NJ, USA

2. Partnership for Assessment and Accreditation of Scientific Practice, Heidelberg, Germany

3. Valdman Institute of Pharmacology, Pavlov Medical University, St. Petersburg, Russia

4. Ventral Stream Consulting LLC., IL, USA

5. Addex Therapeutics, Geneva, Switzerland

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/13543784.2020.1839047

Reference101 articles.

1. Trends in clinical success rates and therapeutic focus

2. Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009-2018

3. Know your target, know your molecule

4. Framework for advancing rigorous research

5. Rigor and Reproducibility. [cited 2020 May 22]. https://www.nih.gov/research-training/rigor-reproducibility/principles-guidelines-reporting-preclinical-research

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Metabotropic Glutamate Receptor 4 (mGlu4) Positive Allosteric Modulators Lack Efficacy in Rat and Marmoset Models of L-DOPA-Induced Dyskinesia;Journal of Parkinson's Disease;2024-03-05

2. Targeting mGluR group III for the treatment of neurodegenerative diseases;Biomedicine & Pharmacotherapy;2023-12

3. Metabotropic glutamate receptors in Parkinson's disease;International Review of Neurobiology;2023

4. A positive allosteric modulator of mGlu4 receptors restores striatal plasticity in an animal model of l-Dopa-induced dyskinesia;Neuropharmacology;2022-11

5. Group III metabotropic glutamate receptors as promising targets for neuroprotective therapy: Particular emphasis on the role of mGlu4 and mGlu7 receptors;Pharmacology Biochemistry and Behavior;2022-09